Education
About Us
Working with TipRanks
Follow Us
Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
Total Valuation
Allarity Therapeutics has a market cap or net worth of $15.49M. The enterprise value is $7.78M.
Market Cap$15.49M
Enterprise Value$7.78M
Share Statistics
Allarity Therapeutics has 15,802,097 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15,802,097
Owned by Insiders4.71%
Owned by Institutions<0.01%
Financial Efficiency
Allarity Therapeutics’s return on equity (ROE) is -2.08 and return on invested capital (ROIC) is -203.82%.
Return on Equity (ROE)-2.08
Return on Assets (ROA)-1.08
Return on Invested Capital (ROIC)-203.82%
Return on Capital Employed (ROCE)-2.31
Revenue Per Employee0.00
Profits Per Employee-4.09M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Allarity Therapeutics is ―. Allarity Therapeutics’s PEG ratio is >-0.00001.
PE Ratio―
PS Ratio0.00
PB Ratio0.16
Price to Fair Value0.16
Price to FCF-0.10
Price to Operating Cash Flow-1.33
PEG Ratio>-0.00001
Income Statement
In the last 12 months, Allarity Therapeutics had revenue of 0.00 and earned -24.52M in profits. Earnings per share was -15.79.
Revenue0.00
Gross Profit0.00
Operating Income-27.24M
Pretax Income-24.90M
Net Income-24.52M
EBITDA-24.23M
Earnings Per Share (EPS)-15.79
Cash Flow
In the last 12 months, operating cash flow was -14.78M and capital expenditures -298.00K, giving a free cash flow of -15.08M billion.
Operating Cash Flow-14.78M
Free Cash Flow-15.08M
Free Cash Flow per Share-0.95
Dividends & Yields
Allarity Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.18
52-Week Price Change-2.78%
50-Day Moving Average1.23
200-Day Moving Average1.15
Relative Strength Index (RSI)42.79
Average Volume (3m)157.99K
Important Dates
Allarity Therapeutics upcoming earnings date is May 18, 2026, After Close (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Allarity Therapeutics as a current ratio of 2.06, with Debt / Equity ratio of 0.00%
Current Ratio2.06
Quick Ratio2.06
Debt to Market Cap0.73
Net Debt to EBITDA0.67
Interest Coverage Ratio41.72
Taxes
In the past 12 months, Allarity Therapeutics has paid -381.00K in taxes.
Income Tax-381.00K
Effective Tax Rate0.02
Enterprise Valuation
Allarity Therapeutics EV to EBITDA ratio is 0.60, with an EV/FCF ratio of 0.93.
EV to Sales0.00
EV to EBITDA0.60
EV to Free Cash Flow0.93
EV to Operating Cash Flow0.94
Balance Sheet
Allarity Therapeutics has $16.89M in cash and marketable securities with $1.39M in debt, giving a net cash position of $15.51M billion.
Cash & Marketable Securities$16.89M
Total Debt$1.39M
Net Cash$15.51M
Net Cash Per Share$0.98
Tangible Book Value Per Share$7.50
Margins
Gross margin is -333.33%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-333.33%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Allarity Therapeutics is $9.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$9.50
Price Target Upside796.23% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast99.82%